MRNS Marinus Pharmaceuticals
- 1.510
- +0.060+4.14%
- 1.520
- +0.010+0.65%
Marinus Pharmaceuticals News
Truist Securities: Maintaining Marinus Pharma (MRNS.US) rating, adjusted from buy to buy rating, and adjusted target price from $25.00 to $10.00.
RBC Capital Downgrades Marinus Pharma to Sector Perform, Lowers Price Target to $3
Baird: Marinus Pharma (MRNS.US) rating was downgraded from being superior to the market to a neutral rating, and the target price was adjusted from $20.00 to $2.00.
Marinus Pharma Analyst Ratings
HC Wainwright & Co. : Marinus Pharma (MRNS.US) rating was reaffirmed and adjusted from buy to buy, with a target price of $27.00.
HC Wainwright & Co. Reiterates Buy on Marinus Pharma, Maintains $27 Price Target
Royal Bank of Canada: Marinus Pharma (MRNS.US) rating was downgraded from being superior to the market to being equal to the general market, and the target price was adjusted from $24.00 to $3.00.
Marinus Pharma Analyst Ratings
Maintaining Buy Rating on Marinus Pharmaceuticals: Confidence in Research and Strategic Financial Health
Marinus Pharma Analyst Ratings
Cantor Fitzgerald Reiterates Overweight on Marinus Pharma, Maintains $28 Price Target
Buy Rating Affirmed for Marinus Pharmaceuticals With Promising Outlook for Ganaxolone in RSE Treatment
Marinus Pharma Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Marinus Pharma, Maintains $27 Price Target
Oppenheimer Maintains Perform on Marinus Pharma, Maintains $9 Price Target
Marinus Pharmaceuticals Earns Buy Rating From Analyst on Strong Sales and Promising Pipeline
Marinus Pharma Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Marinus Pharma, Maintains $27 Price Target
Optimistic Buy Rating for Marinus Pharmaceuticals Based on Promising Clinical Trials and NDA Potential
Buy Rating Affirmed for Marinus Pharmaceuticals Amid Strong Q4 Sales and Promising Clinical Trials
Analysis
Price Target
No Data
